OCRF Now Accepting Applications for 2016 Research Grants
OCRF Now Accepting Applications for 2016 Research Grants
We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.
News
The New York Times Publishes OCRF’s Letter to the Editor 3/...
The New York Times Publishes OCRF’s Letter to the Editor 3/30/15
In response to the “Angelina Jolie Pitt: Diary of a Surgery,” Op-Ed, published in The New York Times on March 24, 2015, OCRF co-wrote a Letter to the Editor along with Ovarian Cancer National Alliance, reminding readers that there is still no early detection method for ovarian cancer. We’re grateful to once again have the … Continued
Microenvironment Regulates Tumor Suppressor miRNA
Microenvironment Regulates Tumor Suppressor miRNA
(April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused methylation mediated decrease in the expression of miR-193b in the tumor cells. … Continued
Population Distribution of Lifetime Risk of Ovarian Cancer ...
Population Distribution of Lifetime Risk of Ovarian Cancer in the US
(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population. In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle factors. Leigh Pierce, PhD and … Continued
Our Response to Angelina
Our Response to Angelina
Angelina Jolie Pitt recently announced that she has had her ovaries and fallopian tubes removed in order to reduce her risk of ovarian cancer. Ms. Jolie Pitt had previous shared that she has a mutation in the BRCA gene, which increases her risk of breast and ovarian cancers. The Alliance received many calls and requests … Continued
Intraperitoneal Chemo Associated with Long-Term Survival Ad...
Intraperitoneal Chemo Associated with Long-Term Survival Advantage
(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer. The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number … Continued
Partner Member Profile: Ovarian Cancer Alliance of Greater ...
Partner Member Profile: Ovarian Cancer Alliance of Greater Cincinnati
The Ovarian Cancer Alliance of Greater Cincinnati (OCAGC) became a Partner Member of the Alliance in October 2010. “It’s been a very positive partnership,” says Martha Farr, an ovarian cancer survivor and co-chair of OCAGC’s Board of Trustees. The group started almost a decade ago, hosting an annual walk to raise awareness. Eventually, the volunteers … Continued
Decisions on a Knife-Edge: Risks and Benefits of Fallopian ...
Decisions on a Knife-Edge: Risks and Benefits of Fallopian Tube Removal
(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer. Removing only the fallopian tubes will avoid forcing a woman into early menopause, which is an appealing option for many women. Yet it’s not … Continued
Tailored Surgical Approach Leads to Better Outcomes in Ovar...
Tailored Surgical Approach Leads to Better Outcomes in Ovarian Cancer
(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival. The work was funded in part by an OCRF research grant to Anil Sood, MD. The results are summarized in an article in Nature … Continued
Ovarian Cancer Research Fund and National Sponsor QVC Expan...
Ovarian Cancer Research Fund and National Sponsor QVC Expand Woman to Woman Program
Gynecologic Cancer Patients to Receive New Support in Baltimore, MD and Portland, OR WEST CHESTER, Pa (February 23, 2015) —Ovarian Cancer Research Fund (OCRF) and QVC® today announced two new Woman to Woman grant recipients: Mercy Medical Center in Baltimore, MD, and Oregon Health and Science University in Portland, OR. The new sites are part … Continued
OCRF Research Finds New Therapeutic Strategy for Ovarian Ca...
OCRF Research Finds New Therapeutic Strategy for Ovarian Cancer
(February 17, 2015) OCRF-funded researchers at The Wistar Institute have identified a new therapeutic target in clear cell ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease. The findings were published online by the journal Nature Medicine. The research was made possible in part … Continued
New Tool Could Speed Development of Ovarian Cancer Drugs
New Tool Could Speed Development of Ovarian Cancer Drugs
(February 13, 2015) University of Chicago Medicine researchers, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has … Continued